ANAB Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.04 |
| 52 Week High | US$27.50 |
| 52 Week Low | US$13.36 |
| Beta | -0.31 |
| 1 Month Change | 27.37% |
| 3 Month Change | -0.95% |
| 1 Year Change | 32.28% |
| 3 Year Change | 2.62% |
| 5 Year Change | -67.79% |
| Change since IPO | 47.29% |
Recent News & Updates
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Recent updates
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business
Jul 28Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 09AnaptysBio EPS beats by $0.03, beats on revenue
May 04Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
Mar 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 28Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth
Feb 10Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters
Dec 19Shareholder Returns
| ANAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | 0.7% | 1.2% |
| 1Y | 32.3% | 5.0% | 27.7% |
Return vs Industry: ANAB exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: ANAB exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| ANAB volatility | |
|---|---|
| ANAB Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ANAB has not had significant price volatility in the past 3 months.
Volatility Over Time: ANAB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 117 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| ANAB fundamental statistics | |
|---|---|
| Market cap | US$654.28m |
| Earnings (TTM) | -US$163.30m |
| Revenue (TTM) | US$22.96m |
29.8x
P/S Ratio-4.2x
P/E RatioIs ANAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANAB income statement (TTM) | |
|---|---|
| Revenue | US$22.96m |
| Cost of Revenue | US$134.37m |
| Gross Profit | -US$111.41m |
| Other Expenses | US$51.89m |
| Earnings | -US$163.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.98 |
| Gross Margin | -485.18% |
| Net Profit Margin | -711.18% |
| Debt/Equity Ratio | 649.2% |
How did ANAB perform over the long term?
See historical performance and comparison